Luspatercept initiated at the maximum-approved dose in transfusion-dependent lower-risk myelodysplastic syndromes: Interim analysis from maxilusAmer M. Zeidan, Matteo Della Porta, Valeria Santini et al.|Blood|2025Cited by 1